Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2019 | 1 |
2022 | 1 |
2023 | 0 |
Search Results
3 results
Results by year
Citations
1 article found by citation matching
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Alzheimers Res Ther. 2018.
PMID: 30591071
Free PMC article.
Search results
Filters applied: . Clear all
Page 1
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, Tan L, Mok V, Yu JT.
Dou KX, et al.
Alzheimers Res Ther. 2018 Dec 27;10(1):126. doi: 10.1186/s13195-018-0457-9.
Alzheimers Res Ther. 2018.
PMID: 30591071
Free PMC article.
BACKGROUND: Cholinesterase inhibitors and memantine have been approved for management of Alzheimer's disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. ...METHODS: We se …
BACKGROUND: Cholinesterase inhibitors and memantine have been approved for management of Alzheimer's d …
Item in Clipboard
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC.
Veroniki AA, et al.
BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012.
BMJ Open. 2022.
PMID: 35473731
Free PMC article.
OBJECTIVE: To examine the comparative efficacy and safety of cognitive enhancers by patient characteristics for managing Alzheimer's dementia (AD). ...We appraised study quality with the Cochrane risk-of-bias. We conducted a two-stage random-effects …
OBJECTIVE: To examine the comparative efficacy and safety of cognitive enhancers by patient characteristics for managing Al …
Item in Clipboard
Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
Jin BR, Liu HY.
Jin BR, et al.
Neural Regen Res. 2019 May;14(5):805-816. doi: 10.4103/1673-5374.249228.
Neural Regen Res. 2019.
PMID: 30688266
Free PMC article.
DATA SELECTION: Randomized controlled trials on donepezil, galantamine, rivastigmine, and memantine as monotherapy in the treatment of vascular cognitive impairment were included. A Bayesian network meta-analysis was conducted. OUT …
DATA SELECTION: Randomized controlled trials on donepezil, galantamine, rivastigmine, and memantine as monothera …
Item in Clipboard
Cite
Cite